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CDK-Independent Activation of Estrogen
Receptor by Cyclin D1
Renate M. L. Zwijsen,* Ellen Wientjens,* in particular breast cancer (Lammie et al., 1991; Schuur-
ing et al., 1992; Bartkova et al., 1994, 1995). We andRob Klompmaker,* Jeroen van der Sman,*
others demonstrated that cyclin D1 overexpression re-Rene´ Bernards,† and Rob J. A. M. Michalides*
duces the growth requirement for mitogens in estrogen-*Department of Tumor Biology
responsive breast tumor cells (Musgrove et al., 1994;†Department of Molecular Carcinogenesis
Reeves et al., 1995; Zwijsen et al., 1996). Consistent withThe Netherlands Cancer Institute
this result, overexpressionof cyclin D1 in mammarycells(Antoni van Leeuwenhoekhuis)
of transgenic mice predisposes them to breast cancerPlesmanlaan 121
(Wang et al., 1994). Moreover, it was shown recently that1066 CX Amsterdam
cyclin D1–deficient mice have a defect in proliferation ofThe Netherlands
the estrogen-responsive breast epithelium during preg-
nancy (Fantl et al., 1995; Sicinski et al., 1995). Taken
together, these results suggest a critical role for cyclinSummary
D1 in proliferation of breast epithelium.
Estrogens act via binding toa specificestrogen recep-Both cyclin D1 and estrogens have an essential role
tor (ER), which belongs to the conserved family of ste-in regulating proliferation of breast epithelial cells. We
roid and thyroid hormone receptors. The receptor is ashow here a novel role for cyclin D1 in growth regula-
66 kDa nuclear regulatory protein that functions as ation of estrogen-responsive tissues by potentiating
hormone-activated transcription factor. Receptor acti-transcription of estrogen receptor–regulated genes.
vation is thought to be a consequence of ligand-inducedCyclin D1 mediates this activation independent of
conformational changes in the structure of the ER (Ku-complex formation to a CDK partner. Cyclin D1 acti-
mar and Chambon, 1988; Tsai et al., 1988). Extracellularvates estrogen receptor–mediated transcription in the
17b-estradiol freely diffuses across the cell membraneabsence of estrogen and enhances transcription in
and binds ER, leading to ER dimerization and transloca-its presence. The activation of estrogen receptor by
tion to the nucleus. The estrogen–ER complex bindscyclin D1 is not inhibited by anti-estrogens. A direct
with high affinity to a well-defined 13 bp palindromicphysical binding of cyclin D1 to the hormone binding
sequence, i.e., the estrogen response element (ERE)domain of the estrogen receptor results in an in-
(Evans, 1988; Kumar and Chambon, 1988; Beato et al.,creased binding of the receptor to estrogen response
1995). The enhancer-like ERE sequences are locatedelement sequences, and upregulates estrogen recep-
near or within estrogen-responsive genes (Beato, 1991).
tor–mediated transcription. These results highlight a
After ERE binding, the liganded ER activates transcrip-
novel role for cyclin D1 as a CDK-independent activa-
tion by an as yet unknown mechanism(s) resulting intor of the estrogen receptor.
stimulation of proliferation (Dubik and Shiu, 1988; Weisz
and Bresciani, 1988). A direct link between 17b–estra-
Introduction diol-mediated proliferation and ER-mediated transcrip-
tion is strongly supported by in vivo and in vitro studies
Cyclins have been identified as positive regulatory sub- using anti-estrogens (DeFriend et al., 1994). Anti-estro-
units of a class of protein kinases termed cyclin-depen- gens inhibit expression of estrogen-regulated genes and
dent kinases (CDKs). These protein kinases have been reduce proliferation of ER-positive breast cells, whereas
shown to be important regulators of major cell cycle 17b-estradiol is a mitogen for breast epithelium (Dubik
transitions in a number of diverse eukaryotic systems. and Shiu, 1988; Weisz and Bresciani, 1988; DeFriend et
In mammalian cells, at least six different cyclin types al., 1994). Here we report an unexpected relationship
have been identified, which act at specific stages of the between cyclin D1 and ER, which has important implica-
cell cycle. A transient accumulation of cyclin proteins tions for our understanding of proliferation of normal
results in activation of their CDK partners and subse- breast epithelium and its deregulation in breast cancer.
quently in phosphorylation of target proteins (Resnitzky
and Reed, 1995; Weinberg, 1995). These protein phos- Results
phorylation cascades are thought to play a crucial role
in the various cell cycle transitions. Cyclin D1 Enhances Transcription
D-type cyclins are strongly implicated in controlling of ERE-Responsive Genes
progression through the G1 phase of the cell cycle. Independent of a CDK Partner
Three closely related human D-type cyclins have been Activation of ERE-containing genes can be elicited in
identified (Inaba et al., 1992; Xiong et al., 1992), all of ER-positive cells by treatment with 17b-estradiol and
which interact with and activate CDK4 and CDK6, al- can be measured by means of a chloramphenicol acetyl
though they have specialized functions in distinct cell transferase (CAT) reporter construct with an upstream
types (Matsushime et al., 1991; Motokura et al., 1992). ERE site in these cells (Klein-Hitpass et al., 1986, 1988).
Among the D-type cyclins, cyclin D1 has been impli- Using this system, we have investigated the effect of
cated most strongly in oncogenesis. Amplification and cyclin D1 in combination with its associated kinase
overexpression of the gene encoding cyclin D1 was fre- CDK4 on ERE-responsive transcription in the well-differ-
entiated and estrogen-responsive T47D breast cancerquently observed in several types of human neoplasia,
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Figure 1. Cyclin D1 Potentiates ERE-Responsive Gene Transcription in the Presence of 17b-estradiol
(A) The effect of cyclin D1 and its associated kinase activity on ERE-mediated transcription. An ERE-reporter construct was used in transient
transfections of T47D breast cancer cells (Klein-Hitpass et al., 1986, 1988) together with wild-type cyclin D1, CDK4, or with mutants of cyclin
D1, which are unable to bind to CDK4 (cyclin D1-KE), or with retinoblastoma protein pRb (cyclin D1-GH) or a catalytic inactive mutant of
CDK4 (CDK4-DN). pCMV-luciferase (0.5 mg) served as an internal control. The relative CAT activity was calculated by normalizing to the
luciferase activity and was divided by the ERE-CAT activity in the presence of 17b-estradiol (10 nM).
(B) The effects of CDKs on regulation of ERE-mediated transcription by cyclin D1. Cyclin D1 (mutants) in combination with CDKs (2.5 mg each)
were cotransfected with the ERE-reporter construct in T47D cells. The relative CAT activity was calculated by normalizing to the luciferase
activity and was divided by the ERE-CAT activity in the presence of 17b-estradiol (10 nM).
(C) The effect of p16INK4 in ectopic cyclin D1/CDK4 expressing cells on ERE-mediated transcription. One microgram cyclin D1 and CDK4
expression vector was used in an ERE-dependent system, and for p16INK4 the amount was variable: 1 5 0.5 mg; 2 5 1.0 mg; 3 5 5.0 mg. CAT
activities were quantified by a phase separation assay (Seed and Sheen, 1988) and represent an average of three independent transfection
studies. The relative CAT activity was calculated by normalizing to the luciferase activity, and was divided by the ERE-CAT activity in the
presence of 17b-estradiol (10 nM).
(D) Cyclin D1 does not affect phosphorylation status of ER. ER-negative U2-OS cells were transfected with k-Ras (lane 1), control plasmid
(lane 2), HA-epitope tagged ER (lane 3 and 6), HA-ER and cyclin D1 (lane 4 and 7), and HA-ER and dominant negative CDK4 (lane 5 and 8)
in the presence (lanes 1–5) and absence (lanes 6–8) of 17b-estradiol. After transfection, cells were in vivo labeled with [32P]orthophosphate
and immunoprecipitated with a monoclonal antibody directed against HA-tag (12CA5).
cell line. Figure 1 shows that cyclin D1 is a strong en- did not enhance transcription of ERE-CAT, nordid CDK4
alone (Figure 1A). To verify that a CDK was not requiredhancer of ERE-responsive gene transcription in the
presence of 17b-estradiol (10 nM). The activity of the in this process, a mutant of cyclin D1 (cyclin D1-KE) was
used, which carries a mutation in the cyclin box. ThisERE-containing reporter construct increased when co-
transfected with increasing amounts of cyclin D1 ex- mutant cyclin D1 fails to bind CDKs and as a result is
unable to mediate phosphorylation of pocket proteinspression vector. Up to 7-fold potentiation was seen as
compared to its basal level of 17b–estradiol-activated (Hinds et al., 1994; Beijersbergen et al., 1995). Like wild-
type cyclin D1, the cyclin D1-KE mutant potentiatedtranscription, which was arbitrarily set at 1 (Figure 1A).
The importance of the ERE in this effect is supported transcriptional activation of ER in a dose-dependent
manner. Cotransfection of CDK4 and cyclin D1-KE didby the fact that cyclin D1 did not stimulate the activity
of a reporter construct that lacked an ERE (Figure 3A). not influence the cyclin D1 effect on transactivation (Fig-
ure 1B). This finding supports the notion that the effectCyclin D1 in combination with its kinase partner CDK4
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of cyclin D1 on ER is independent of its ability to activate
a CDK partner. Consistent with this notion, binding of
cyclin D1 to a CDK that lacks intrinsic kinase activity,
such as the dominant negative CDK4 mutant (CDK4 DN)
or CDK2 (which is not activated by cyclin D1; Ewen et
al., 1993), prevented the stimulatory effect of cyclin D1.
In addition, a CDK that cannot bind to cyclin D1, CDC-2,
was ineffective in preventing transactivation by cyclin
D1 (Figure 1B). These data strongly suggest that the
kinase activity of any cyclin D1–CDK complex is irrele-
vant in activating ERE-mediated transcription. Signifi-
cantly, cotransfection of cyclin D1 and CDK4 with
p16INK4, a CDK inhibitor that competes with cyclin D1 for
binding to CDK4 (Parry et al., 1995), enhanced transcrip-
tion to a level comparable with that induced by cyclin
D1 alone (Figure 1C). Taken together, these data indicate
that “free” cyclin D1 can enhance ERE-mediated tran-
scription, whereas CDK-bound cyclin D1 is inactive.
It has recently been shown that ER can be activated
by phosphorylation induced by mitogens and/or onco-
genes (Kato et al., 1995). To investigate the ability of
cyclin D1 to induce phosphorylation of ER, ER-negative
cells were transfected with HA–epitope-tagged ER in
combination with cyclin D1 or dominant negative CDK4.
Transiently transfected cells were labeled with [32P]-
orthophosphate, and lysates were subjected to immu-
Figure 2. The Specific Action of Cyclin D1 on ERE-Responsive Tran-noprecipitation with a monoclonal antibody directed
scription
against the HA-tag. As expected, expression of k-Ras
(A) The specificity of cyclin D1 in activation of ERE-mediated tran-
resulted in phosphorylation of ER (Figure 1D) (Kato et scription. The effect of wild-type cyclins (2.5 mg) was tested using
al., 1995). The phosphorylation status of ER, however, an ERE-reporter construct in transient transfection studies of T47D
was not altered in cells cotransfected with ER and cyclin breast cancer cells in the presence of 17b-estradiol (10 nM). The
relative CAT activity was calculated by normalizing to the internalD1 or ER and CDK4 DN in the presence and absence
control and was divided by ERE-CAT activity in the presence ofof hormone (Figure 1D). Thus, alterations in phosphory-
17b-estradiol.lation of ER are not responsible for the observed activa-
(B) The effect of cyclin D1 on PRE-mediated transcription. A PRE-
tion of ERE-responsive transcription by cyclin D1. To reporter construct was used in transient transfections of T47D cells
investigate whether the motif in cyclin D1 that mediates together with cyclin D1 (2.5 mg) in the presence or absence of 10
binding to the retinoblastoma protein (pRB) was re- nM progestin Org 2058. The relative CAT activity was calculated by
normalizing to the internal control and was divided by PRE-lucifer-quired for activation of ER, another cyclin D1 mutant
ase activity in the absence of progestin.(cyclin D1-GH) was used. Cyclin D1-GH carries a muta-
(C) The effect of cyclin D1 on ERE-TATA-reporter construct. An ERE-tion in the LXCXE motif, and this mutation renders the
TATA-luciferase constructwas used in transient transfection studies
protein unable to bind to pocket proteins, such as pRB with T47D cells in combination of cyclin D1. The relative luciferase
(Dowdy et al., 1993; Hinds et al., 1994). Figure 1A shows activity was calculated by normalizing to the internal control and
that this cyclin D1 mutant enhanced the expression of was divided by ERE-luciferase activity in the absence of estrogen.
the ERE-CAT reporter construct to the same extent as
wild-type cyclin D1, indicating that this enhancement of
both in the presence and absence of Org 2058. In addi-transcription was independent of an intact pRB-binding
tion, cyclin D1 did not affect glucocorticoid receptor-motif in cyclin D1.
mediated transcription (data not shown). Thus, cyclinThe uniqueness of cyclin D1 among the cyclins in the
D1-mediated activation is not general among steroidactivation of ERE-mediated transcription is illustrated
receptors. To ask whether the cyclin D1 activation ofin Figure 2. Cyclin D1 potentiated ER-mediated tran-
ER depends on the promoter context, we generated ascription, whereas the other D type cyclins (which were
second reporter construct in which the ERE is upstreamexpressed at comparable levels, data not shown) did
of a core promoter (TATA box only: ERE-TATA-reporter).not. The specific effect of cyclin D1 on ERE-dependent
As shown in Figure 2C, cyclin D1 gave similar levels oftranscription was further demonstrated by the inability
transactivation in the presence and absence of 17b-of cyclin E, cyclin A, cyclin B1, and cyclin B2 to activate
estradiol when tested on a construct containing EREER-mediated transactivation. To study whether cyclin
sequence linked to a TATA promoter. This result sug-D1 activates transcription mediated by other steroid re-
gests that the cyclin D1 action is not promoter specific.ceptors, we tested the effect of cyclin D1 on the proges-
terone receptor (PR) using a progesterone response ele-
The Effect of Cyclin D1 on ERE-Responsivement (PRE)-containing reporter construct (Figure 2B).
Transcription Is Hormone IndependentAs expected, transcription of the PRE-reporter con-
To study the contribution of estrogen to the observedstruct was induced by a progestin, Org 2058. Cyclin D1
failed, however, to enhance PRE-mediated transcription enhanced transcription of ERE-containing genes by
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cyclin D1, T47D cells were transiently transfected with
cyclin D1 and the ERE-reporter construct, and were
maintained in medium with various concentrations of
17b-estradiol. Figure 3A demonstrates that the activity
of the ERE-CAT reporter construct was dramatically en-
hanced in T47D cells by 17b-estradiol, as expected. The
activity of the ERE-CAT reporter construct, however,
was enhanced substantially by cotransfection of cyclin
D1 expression vector at all concentrations of 17b-estra-
diol tested. In the absence of ligand, cyclin D1 was able
to restore the transcriptional activity to levels similar
or even higher than obtained with 17b-estradiol alone
(Figure 3B). These data indicate that cyclin D1 and estro-
gen are synergistic in stimulating estrogen-regulated
transcription, and that cyclin D1 can also act inde-
pendently of estrogen in activating ERE-responsive
transcription. Therefore, cyclin D1 can substitute for
estrogen in activating ER. This may contribute to the
mitogen-independent proliferation in cyclin D1–over-
expressing cells, which is frequently found in breast
tumors (Schuuring et al., 1992; Bartkova et al., 1994;
Michalides et al., 1996). A hormone-independent mech-
anism of action of cyclin D1 is further supported by
experiments with the anti-estrogen 4-hydroxytamoxi-
fen, which binds to the estrogen receptor in a manner
that is competitive with estrogen but fails to activate
gene transcription (Berry et al., 1990). Figure 3C shows
that 4-hydroxytamoxifen antagonized the effect of 17b-
estradiol on transcriptional activation, but did not pre-
vent transcriptional potentiation by cyclin D1. Also, a
pure anti-estrogen ICI 164,384, which blocks both acti-
vation functions of ER (AF-1 and AF-2), did not prevent
cyclin D1 transactivation. These data indicate that cyclin
D1 was effective in activating transcription of ERE-con-
taining genes in cells harboring ERs occupied with 17b-
estradiol, as well as in cells with unliganded ERs.
Cyclin D1 Action Is ER-Mediated
Because estrogen was not required for this cyclin D1
action, the question arose whether ER itself was re-
quired for the effect of cyclin D1 on ERE-responsive
transcription. Therefore, we used the human osteosar-
coma cell line U2-OS and cervical carcinoma cell line
HeLa, both of which have negligible levels of ER. Co-
transfection of cyclin D1 and the ERE-reporter construct
in thesecells did not increase ERE-responsive transcrip-
tion, whereas cotransfection of these genes with human
ER expression vector led to activation of the ERE-CAT
(Figure 4A). As in T47D cells, cyclin D1 stimulated tran-
Figure 3. Cyclin D1 Enhances ERE-Responsive Gene Transcription scription both in the presence and absence of 17b-
Independently of Ligand Activation of ER estradiol in ER-transfected cells. Thus, cyclin D1 acts
(A) The effect of estrogen and cyclin D1 on ERE-responsive tran-
scription activity. T47D cells were maintained in medium containing
various concentrations of 17b-estradiol, and were transfected with
an ERE-reporter construct or a reporter construct that lacked ERE struct, as described in Experimental Procedures. The amount of
(DERE) in concert with cyclin D1 expression vector. cyclin D1 plasmid used for transient transfections was 5 mg per
(B) Cyclin D1 activates ERE-CAT transcription in 17b-estradiol free 10 cm plate in (A) and (C), and variable in (B). During the experiment,
conditions. T47D cells were transfected with various amounts of cells were maintained in phenol red–free DMEM supplemented with
cyclin D1 constructs in the absence of ligand. insulin (10 mg/ml) and transferrin (10 mg/ml); cells were treated with
(C) Cyclin D1 induces ERE-gene expression by a hormone-indepen- 17b-estradiol (0.1 nM) and/or antiestrogen (100 nM) as indicated.
dent mechanism. The effect of cyclin D1 on ERE-responsive tran- After 40 hr, cells were lysed and assayed for both CAT activity and
scription was examined in T47D cells treated with 17b-estradiol luciferaseactivity (Promega, Luciferase system). Data areexpressed
and/or the antiestrogens 4-hydroxytamoxifen and ICI 164,384. as relative CAT activity compared with basal CAT level in the ab-
T47D cells were transfected with ERE-reporter plasmid, cyclin D1 sence of 17b-estradiol: E2, 17b-estradiol; D1, cyclin D1; 4HT, trans-
expression vector, and the internal control pCMV-luciferase con- 4-hydroxytamoxifen; DERE, pCAT lacking ERE.
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Figure 4. The Potentiation of Gene Activation by Cyclin D1 Is ER Mediated
(A) ER is involved in modulation of ERE-responsive gene transcription triggered by cyclin D1. The human ER-negative U2-OS and HeLa cell
lines were used to investigate the role of ER in potentiation of ERE-CAT transcription activity by cyclin D1. Together with ERE-CAT and pCMV-
luciferase plasmids, cells were transfected with cyclin D1 in combination with human ER and tested for transcription of the CAT reporter
construct. The CAT activity was normalized to luciferase activity and was divided by the basal CAT activity of cells lacking ER in order to
obtain the “relative CAT activity” as indicated: E2, 17b-estradiol; D1, cyclin D1: 1 5 0.25 mg, 2 5 1.0 mg; ER, estrogen receptor.
(B) Cyclin D1 does not modulate ER protein synthesis. U2-OS cells transfected with ER and/or cyclin D1 were subjected to immunoblotting
using an antibody directed against ER.
through the ER to enhance transcription of ERE-con- ER, where the transactivational activity in this complex is
provided by the hormone-dependent activation domaintaining genes. The ER protein levels in U2-OS cells con-
taining transiently expressed cyclin D1 were similar to AF-2 in ER. GAL4-dependent CAT transcription was
minimally stimulated when either GAL4-D1 or ER werethose seen in cells without cotransfected cyclin D1 (Fig-
ure 4B). Therefore, the enhancement of ERE-responsive transfected separately, as is shown in Figure 5B. CAT
activity was significantly increased, however, by GAL4-gene transcription by cyclin D1 was not due to a modula-
tion of ER protein levels. D1 in combination with ER, suggesting an interaction in
vivo between cyclin D1 and liganded ER. Consistent
with the data obtained in the ERE-CAT assays (FigureCyclin D1 Binds to (Un)liganded ER In Vivo
and In Vitro 1), CDK4 and progesterone receptor (PR-B) act in this
in vivo binding assay as a competitor and as a negativeCyclin D1 could well activate ER-mediated transcription
through direct binding to ER. When we mixed in vitro– control, respectively. To investigate an in vivo binding
between cyclin D1 and unliganded ER, we next gener-translated 35S–methionine labeled human ER with GST-
cyclin D1 protein in an in vitro binding assay, we did ated an ER fusion protein containing a herpes simplex
virus VP16 activation domain (VP16-ER). Cotransfectionindeed observe specific binding of ER to GST-cyclin D1
(Figure 5A). Binding was observed both with liganded of two chimeric expression vectors, GAL4-D1 and VP16-
ER, in combination with a GAL4-dependent reporteras well as with unliganded receptor (lanes 2 and 3). To
investigate whether cyclin D1 also binds to both li- construct resulted in a significant increase in transcrip-
tion of the reporter construct (Figure 5C). This resultganded ER and unliganded ER in vivo, we used a mam-
malian two-hybrid assay. To test the in vivo binding suggests that cyclin D1 interacts with unliganded ER in
vivo.between cyclin D1 and liganded ER, a chimeric expres-
sion vector harboring cyclin D1 fused to a GAL4 DNA To get an impression of the relative strength of the
ER–cyclin D1 and cyclin D1–CDK4 interactions, we per-binding domain (GAL4-D1) was generated and cotrans-
fected with ER and a GAL4-site containing reporter formed transfection studies with GAL4-D1 in combina-
tion with VP16-CDK4 (Figure 5C). Using the mammalianplasmid into U2-OS cells. Transcription of the reporter
construct should be stimulated in the presence of 17b- two-hybrid system, the relative activity of GAL4-D1/
VP16-CDK4 was increased 3-fold, as compared withestradiol if a complex is formed between GAL4-D1 and
Cell
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Figure 5. Cyclin D1 Interacts with (Un)liganded ER
(A) The in vitro interaction between cyclin D1 and ER. The in vitro interaction between cyclin D1 fused to glutathione-S-transferase (GST) and
35S-labeled ER was studied both in the presence and absence of 17b-estradiol. GST-cyclin D1 or control GST protein were mixed with 35S-
labeled ER and immobilized on glutathion-agarose beads to establish in vitro binding. Lane 1 represents 10% of ER input, lanes 2 and 3
represent the amount of ER bound to GST-cyclin D1, and lanes 4 and 5 represent the amount of ER bound to GST protein.
(B) The in vivo interaction between cyclin D1 and ER in the presence of 17b-estradiol. The in vivo interaction between cyclin D1 and liganded
ER was studied using a mammalian two hybrid assay with a chimeric protein GAL4-D1, which contains the GAL4 DNA binding domain (amino
acid 1–147) fused to cyclin D1, in combination with ER that acts as a hormone-activated transcription factor. As a result of protein–protein
interaction, hybrid proteins are able to stimulate transcription of a GAL4-dependent reporter construct (G5BCAT). This reporter construct,
G5BCAT, contains five GAL4 binding sites 59 to the E1B TATA sequence (Kim et al., 1992). The human steroid progesterone receptor (PR-B)
served as negative control. The unliganded ER also did not stimulate CAT transcription (data not shown).
(C) The in vivo interaction between cyclin D1 and ER in the presence and absence of 17b-estradiol. The in vivo interaction between unliganded
ER and cyclin D1 was studied using a mammalian two-hybrid assay with two chimeric proteins, VP16-ER (which contains the herpes simplex
virus VP16 activation domain fused to ER) and GAL4-D1, in the GAL4 dependent reporter system as described in Figure 5B. GAL4-D1 in
combination with VP16-CDK4 and dimerized ER served as positive controls. The results are expressed as average of at least three separate
experiments 6 SD, and related to CAT activity of a transfection using vector containing GAL4 DNA binding domain in combination of G5BCAT
reporter vector in the presence of 10 nM ligand (17b-estradiol or Org 2058) for panel B and in the absence of ligand for panel C: E2, 17b-
estradiol; D1, cyclin D1; ER, estrogen receptor; (asterisks)P # 0.05.
(D) In vivo interaction between cyclin D1 and ER using immunoprecipitation. HA-tagged ER and cyclin D1 were transfected in U2-OS cells
and immunoprecipitated using an antibody against HA-epitope tag (12CA5). The HA-ER associated proteins were tested for cyclin D1 by
Western blot analysis. The upper part shows HA-tagged ER and (part of) IgH chains, and the lower part shows cyclin D1 protein. Lanes 1–4
of the Western blot represent HA-tagged ER-transfected cells in combination with cyclin D1 (lanes 3 and 4) in the presence of 17b-estradiol
(lane 1 and 3) or absence of 17b-estradiol (lane 2 and 4).
GAL4-D1/VP16-ER. This finding suggests that, besides cyclin D1 binding by Western blot analysis. Cotransfec-
tion with cyclin D1 resulted in coimmunoprecipitationthe binding of cyclin D1 to its kinase partner CDK4, the
cyclin D1–ER interaction is of physiological importance. of cyclin D1 with liganded as well as with unliganded
ER. Thus, cyclin D1 physically interacts both with li-Immunoprecipitation studies support the in vivo inter-
action between cyclin D1 and (un)liganded ER (Figure ganded and unliganded ER in vivo.
5D). HA-tagged ER constructs were transfected to-
gether with cyclin D1 into U2-OS cells and maintained Cyclin D1 Acts through the EF Region of ER
In order to localize the ER domain that responds toin 17b–estradiol-enriched or -free conditions. HA-ER fu-
sion protein was immunoprecipitated and analyzed for cyclin D1, we have used chimeras inwhich either regions
Cyclin D1 Activates ER
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Figure 6. Involvement of Cyclin D1 in Binding of ER to ERE Sequences
(A) Analysis of protein-ERE complexes in response to cyclin D1 and 17b-estradiol. Extracts were prepared of U2-OS cells transfected with
human ER in combination with cyclin D1, and subjected to mobility shift analysis as described in Experimental Procedures. Lanes 1 and 5
show the effect on ERE binding of transfected U2-OS cells with ER, lanes 2 and 6 represent ER and cyclin D1 cotransfectants, lanes 3 and
7 represent ER, cyclin D1, and CDK4 cotransfectants, and lanes 4 and 8 represent ER and CDK4 cotransfectants. Cell extracts were maintained
in 10 nM 17b-estradiol (lanes 1–4) or in 17b-estradiol free conditions (lanes 5–8).
(B) ER identification of ERE-associated protein complex. Protein identificationof ERE-associated complexes was tested by antibody-dependent
supershifts using antibodies directed against ER. Lanes 1 and 4 represent ER transfectants, lanes 2, 3, 5, and 6 represent ER and cyclin D1
transfectants in the presence of 17b-estradiol (lanes 1, 2, 4, and 5) or absence of ligand (lanes 3 and 6). The transfectants were subjected to
mobility shift analysis in the presence of ER antibody (lanes 3–6).
(C) Activation of ER by cyclin D1 does not require sequence- specific DNA binding, and cyclin D1 specifically activates the EF region of ER.
U2-OS cells were transfected with 1.5 mg of a vector encoding full-length ER, AB region of ER or EF region of ER fused to GAL4 DNA binding
domain yielding GAL-ER, GAL-ER(AB), and GAL-ER(EF), respectively. Transfection studies were performed together with cyclin D1 expression
vector (1.5 mg) and G5BCAT reporter vector (3 mg), and cells were kept in the presence or absence of 10 nM 17b-estradiol. The results are
expressed as relative CAT activity compared with basal CAT level in the absence of ligand.
(D) In vivo binding between cyclin D1 and GAL-ER fusion proteins. Constructs encoding GAL-ER fusion proteins and cyclin D1 were transfected
in U2-OS cells in the presence and absence of 17b-estradiol (E2), and immunoprecipitated using antibody directed against GAL-tag (sc 577,
Santa Cruz). The GAL-ER (full length), GAL-ER(AB), and GAL-ER (EF) associated proteins were tested for cyclin D1 binding by Western blot
analysis as indicated. Lanes 2, 4, 6 and 7 represent cyclin D1 transfected cells. Transfection with a construct encoding the GAL4 DNA binding
domain (GAL-DBD) together with cyclin D1 served as negative control (lane 7).
(E) Direct binding between cyclin D1 and EF-region of ER. Bacterially produced and purified GST-ER(EF) or control GST protein and his-
tagged cyclin D1 (His-D1) were mixed and immobilized on glutathion-agarose beads. Direct in vitro binding was analyzed by Western blotting
using monoclonal antibody directed against cyclin D1. Lane 1 represent 1% of input, lanes 2 and 3 represent the amount of His-D1 bound
to GST-ER(EF) and lanes 4 and 5 represent the amount of His-D1 bound to GST protein.
A/B (amino acids 1–184) or E/F (amino acids 282–595) correlated with binding to ER, we performed transient
transfection experiments (Figure 6D). Immunoprecipita-were fused to the GAL4 DNA binding domain, yielding
GAL-ER(AB) (Ali et al., 1993) and GAL-ER(EF) (Webster tion of GAL fusion proteins, which contain the AB or EF
region of ER, from transiently transfected U2-OS cellet al., 1988). Using these constructs in a GAL4-depen-
dent reporter system in combination with cyclin D1, we extracts, followed by Western blot analysis using a
monoclonal antibody directed against cyclin D1, re-found that the GAL-ER(AB) construct did not respond
to cyclin D1 (Figure 6C). In contrast, cyclin D1 was able vealed that cyclin D1 predominantly binds to the EF
region and not, or at least with lower affinity, to the ABto stimulate transactivation by both GAL-ER(EF) and
GAL-ER wild-type to the same extent (Figure 6C). To region of ER. This binding between cyclin D1 and the
C-terminal domain of ER occurred both in the presenceask whether cyclin D1-mediated transactivation of ER
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as well as in the absence of 17b-estradiol. The interac- associated with a direct physical interaction between
cyclin D1 and ER. Cyclin D1 enhances binding of bothtion between the carboxy-terminal region of ER and
cyclin D1 was also confirmed in a GST pulldown experi- liganded as well as unliganded ER to ERE-sequences.
These data support a model in which cyclin D1-ER inter-ment using bacterially produced and purified His-cyclin
D1 and GST-ER(EF), containing amino acids 340–595 action triggers ER to undergo an activation step by
means of a conformational change. Cyclin D1 interaction(Figure 6E). Since no other mammalian proteins were
present in this experiment, these data indicate that increases binding of ER to ERE sequences and en-
hances transactivation of ER. Together, this activity re-cyclin D1 acts through direct binding to the C-terminal
EF region of ER. sults in a dramatic enhancement of transcription of ERE-
responsive genes.
In contrast to the current view that receptor activationCyclin D1 Enhances Binding of ER
is dependent on binding its cognate ligand, the presentto ERE Sequence
study shows that cyclin D1 also activates ER-mediatedTo investigate whether the cyclin D1 action on transcrip-
transcription in the absence of ligand. In addition, it wastion was due to enhanced ER binding to ERE, we ana-
recently shown that EGF, TGFa, and dopamine also elicitlyzed the binding of ER-ERE complexes in response to
ER-dependent transcription of an ERE-containing gene,cyclin D1 using a gel retardation assay. When transiently
which was not dependent on estrogens (Ignar-Trow-transfected into U2-OS cells and maintained in 17b–
bridge et al., 1993; O’Malley et al., 1995). One possibleestradiol enriched medium, cyclin D1 increased the
mechanism for estrogen receptor activation could beER binding to ERE sequence 3-fold (Figure 6A). Consis-
phosphorylation of the receptor (Zhang et al., 1994; Katotent with data obtained from ERE-CAT and interaction
et al., 1995). Transcriptional activation by ER can beassays, cyclin D1 in combination with CDK4 was less
induced by growth factors through the membrane-asso-effective in stimulating ER binding to ERE sequence.
ciated receptor tyrosine kinase-Ras-Raf-MAPK cas-Analysis of DNA binding complexes in response to hor-
cade, which enhances the activity of AF-1 site in ERmone deprivation revealed that cyclin D1 stimulated ER
molecule via phosphorylation of the Ser-118 residuebinding to ERE, which was absent in cells lacking ec-
(Kato et al., 1995). The present study clearly demon-topic cyclin D1 (Figure 6A). Antibody supershift experi-
strates that cyclin D1 does not enhance phosphorylationments of ERE-associated complexes revealed that ER
of ER. Instead, our data indicate that cyclin D1 actsis present in these ERE-associated complexes (Figure
through direct physical association to activate ER.6B). Thus, cyclin D1 triggers binding of liganded and
Until now, cyclin D1 has been regarded only as a CDKunliganded ER to ERE sequences.
regulator. Via CDK activation, it regulates progressionTo investigate whether cyclin D1 only acts on ER spe-
of cells through the G1 phase of the cell cycle. Overex-cifically bound to an ERE sequence, we used an ER
pression of cyclin D1 causes several effects on the cellfused to GAL4 DNA binding domain in a GAL4-depen-
cycle, including a shortening of the G1 interval, an in-dent reporter system. In this assay, cyclin D1 enhanced
crease of G0/G1 transition, and a decrease of G1/G0GAL4-dependent transcription in a ligand-independent
transition (Resnitzky et al., 1994; Resnitzky and Reed,manner (Figure 6C), indicating that cyclin D1 does not
1995; Zwijsen et al., 1996). The dual activity of cyclinrequire sequence-specific DNA binding by ER for activa-
D1 as activator of ER and mediator of cell cycle progres-tion. These data therefore indicate that cyclin D1 also
sion via cdk kinase activity is thus far unique among theaffects ER activity by enhancing transactivation by ER.
cyclins. Overexpression of cyclin E also shortens G1,In conclusion, cyclin D1 acts by both enhancing the DNA
as does overexpression of cyclin D1 (Resnitzky et al.,binding and transactivation capacity of ER.
1994; Resnitzky and Reed, 1995), but does not affect
ER activation. This finding indicates that perturbed G1
Discussion progression and premature S-phase entry on their own
do not account for activation of ER, and highlights that
The present study establishes a new role for cyclin D1 cyclin D1 acts in this respect via two different mecha-
as a positive regulator of ER-mediated transcription. nisms.
The transcriptional activation was specific in that of all In breast tumor cells, several ER variants have been
cyclins tested only cyclin D1 could enhance ER-medi- identified (Zhang et al., 1993; Wiltschke and Fuqua,
ated transactivation. Furthermore, cyclin D1 could only 1995). Many of these variants are the results of alterna-
stimulate transactivation by ER and not the PR. Impor- tive mRNA splicing and of point mutations, which usually
tantly, activation of ER by cyclin D1 was entirely inde- yield truncated products (Wiltschke and Fuqua, 1995).
pendent of CDK binding and did not require occupancy The ER variants are coexpressed with, and often in ex-
by cognate steroid of the receptor. In normal breast cess of, wild-type ER. In the present study, we have
epithelial cells, estrogen receptors are thought to be used the breast tumor T47D cell line in which small levels
transcriptionally inactive within the cell before binding of ER variants with exon 2, 3, 5, and 7 deletions are
to hormone. Occupancy by hormone results in confor- identified (Wang and Miksicek, 1991; Zhang et al., 1993).
mational change in its cognate receptor protein, which It is very unlikely that the cyclin D1 action is attributed
leads to intranuclear translocation and allows associa- to one of the ER variants in these cells, since cyclin D1
tion with specific DNA sequence in the regulatory region was effective in theER-negative U2-OS cells transfected
of target genes. As a result of ER-ERE binding, transcrip- with wild-type ER cDNA expression vector. Further-
tion of cis-linked target genes will be stimulated. We more, immunofluoresence studies revealed that these
ectopic ER proteins in U2-OS cells are predominatelydemonstrated that ER transactivation by cyclin D1 is
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the transfection, cells were maintained in phenol red-free DMEMlocated in the nucleus, and that cyclin D1 did not modu-
containing insulin/transferrin (10 mg/ml each) or 10 nM ligand (thelate the subcellular localization of ER (data not shown).
estrogen 17b-estradiol or the progestin Org 2058) as indicated.Thus, it appears that the activation of ER by cyclin D1
is not due to a change in ER translocation to the nucleus. Transfection Studies
We have determined that the site of cyclin D1 action The reporter plasmids, ERE-TK-CAT (3 mg) containing the ERE from
the vitellogenin A2 gene or (PRE)2-TK-luc, were transiently trans-is located in the E/F region of liganded as well as unli-
fected into subconfluent T47D cells using the calcium phosphateganded ER. Binding of cyclin D1 to this region could
precipitation technique (Graham and van der Eb, 1973). The expres-modulate the binding of accessory protein(s) of ER, in-
sion vectors used in the transient transfection studies were pCMVcluding Hsp90, Hsp70, p60, p23, and proteins of the
cyclin D1, cyclin D2, cyclin D3, cyclin A, cyclin E, cyclin B1, cyclin
transcriptional machinary (Pratt, 1993). It is conceivable B2, CDC2, CDK2, CDK4, CDK4-DN, cyclin D1-GH, and cyclin D1-
that they assist in the activation of the ER by cyclin D1. KE, which have been described elsewhere (Hinds et al., 1992, 1994).
ER-negative cells were transfected with 0.4 mg human ER constructFor instance, Hsp90 promotes a receptor structure that
(HEGO; Migliaccio et al., 1991). After 40 hr, cells were harvested andis capable of ligand binding. Ligand binding could in-
resuspended in 0.1 M Tris-HCl (pH 8.0), and assayed for luciferaseduce a conformational change in the receptor, which in
activity (Promega, Luciferase system), b-galactosidase activityturn could prevent rebinding of Hsp90, while simultane-
(Tropix, galactolight assay), and/or CAT activity (Seed and Sheen,
ously allowing receptor dimerization. This Hsp, however, 1988).
is an unlikely candidate to assist cyclin D1 in ER activa-
Phosphate Labeling and Immunoprecipitationtion, because (i) it is dissociated from the ER-complex
U2-OS cells were transfected in the presence or absence of serum.after ligand binding, whereas cyclin D1 also activates
After 24 hr, cells were incubated for 1 hr in phosphate-free DMEM,the liganded complex; (ii) the subcellular localization
followed by incubation in phosphate-free DMEM supplementedwithdiffers between Hsp90 and cyclin D1 (cytoplasm versus
1.0 mCi/ml [32P]orthophosphate for 4 hr in the absence of mitogens
nucleus); and (iii) Hsp90 acts on all members of the or in the presence of 17b-estradiol (10 nM) and 10% dialyzed serum.
steroid receptor family, whereas the cyclin D1 action is After labeling, cells were lysed in RIPA buffer1 containing 150 mM
NaCl, 1% NP-40, 50 mM Tris (pH 7.8), 10 mM EDTA, 0.5% deoxycho-restricted to ER.
late, 0.1% SDS, 1 mM PMSF, 5 mg/ml aprotinin, 10 mg/ml trypsinOur data suggest that cyclin D1 is involved in activa-
inhibitor, 10 mg/ml leupeptin, and 10 mM b-glycerophosphate. Thetion of ERE-containing gene transcription. Cyclin D1
lysate was precleared three times with 5 ml of normal mouse serummay therefore contribute to a potentiation of estrogen-
coupled to protein A-Sepharose beads. For immunoprecipitations,
mediated cell proliferation in hormone-responsive tis- the supernatant was incubated with 100 ml of 12CA5 hybridoma
sues, such as breast epithelium. Consistent with this is supernatant, which was coupled to protein A sepharose beads at
48C. After 1 hr, beads werewashed in RIPA buffer, boiled in Laemmli-the recent finding that cyclin D1-deficient mice have
buffer and separated on a 10% SDS-polyacrylamide gel, dried, anda defect in hormone-responsive proliferation of breast
subjected to autoradiography.epithelium (Fantl et al., 1995; Sicinski et al., 1995). These
defects in lobuloalveolar development in cyclin D1-defi-
cient animals were caused by a diminished hormone Western Blot Analysis
responsiveness of the breast tissue and are reminiscent U2-OS cells transfected with ER (0.4 mg), together with cyclin D1 (1
mg), were lysed in extraction buffer (50 mM Tris [pH 7.4], 150 mMof those observed in mice lacking the PR (Lydon et al.,
KCl, 15 mM NaCl, 30 mM MgCl2, 10 mM EGTA, 0.5% NP-40, 1 mM1995). Because the PR gene is an ER target gene, these
PMSF, 5 mg/ml aprotinin, 10 mg/ml trypsin inhibitor, and 10 mg/mldata support the novel mechanism of cyclin D1 pro-
leupeptin). Equal amounts of total cell extracts were separated byposed in this study, and strengthen its physiological
SDS-polyacrylamide gel electrophoresis and blotted to a cellulose
relevance. nitrate membrane. Immunoblot analysis was performed with anti-
Recently, it was shown that overexpression of cyclin cyclin D1 (DCS-6, Progen) and anti-ER (LH2, Novacastra) mono-
D1 renders breast cancer cells less mitogen dependent clonal antibodies, and immunodetection was performed using the
enhanced chemiluminescence system.(Musgrove et al., 1994; Zwijsen et al., 1996). In this con-
text, the present study clearly shows that cyclin D1 can
In Vitro Binding Assayalso enhance transcription of ER-responsive genes
Total bacterial extracts expressing cyclin D1 protein fused to gluta-
without assistance of estrogens by stimulating ER bind- thione-S-transferase (GST) or GST protein alone were generated
ing to ERE-sequences. This cyclin D1 action enables and purified on gluthathione agarose beads. 35S–methionine labeled
cells to bypass the requirement for estrogens and there- ER protein was prepared by in vitro transcription/translation and
incubated with 1 mg GST-cyclin D1 in ELB (250 mM NaCl, 0.1% NP-fore provides a mechanism for estrogen-independent
40, 50 mM Hepes [pH 7.0], and 5 mM EDTA) with 0.5 mM DTT, 1growth of cyclin D1-overexpressing breast tumor cells
mM PMSF, 10 mg/ml aprotinin, and 10 mg/ml leupeptin, bound to(Schuuring et al., 1992; Bartkova et al., 1994; Michalides
gluthathione-agarose beads, washed in ELB, eluted, and fraction-et al., 1996). Our finding that activation of ER by cyclin
ated by SDS-polyacrylamide gel electrophoresis.
D1 cannot be inhibited by the anti-estrogen tamoxifen
raises the possibility that tamoxifen treatment is ineffec- GAL4-Dependent Reporter System
tive in cyclin D1-amplified breast cancers. We are cur- To generate chimeric proteins, A/B region of ER (amino acid 1–184)
or E/F region of ER (282–595), or full-length of ER or cyclin D1rently performing a retrospective clinical study on breast
cDNAs, were inserted in frame downstream of the GAL4 (1–147)cancer biopsies to investigate this possibility in detail.
DNA binding domain fragment or sequence coding for the acidic
activation domain of the Herpes Simplex virus VP16 protein. U2-OS
cells were transfected with 1.5 mg GAL4-D1, ER, PR-B, and CDK4Experimental Procedures
expression vectors in combination with 10 mg G5B-CAT reporter
constructs. As an internal control, 0.5 mg of pCMV-luciferase plasmidCell Lines
was used in the assays. The CAT activity was corrected for differencesHuman T47D, HeLa, and U2-OS cells were cultured in Dulbecco’s
modified Eagle medium (DMEM) with 10% fetal calf serum. During in transfection efficiency by normalizing to luciferase activity.
Cell
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Gel Retardation Assay Ewen, M.E., Sluss, H.K., Sherr, C.J., Matsushime, H., Kato, J., and
Livingston, D.M. (1993). Functional interactions of the retinoblas-A 31-base oligonucleotide ERE probe (59-GATCCGTCAGGTCACAG
TGACCTGATGGATC-39) was used. Equimolar amounts of both toma protein with mammalian D-type cyclins. Cell 73, 487–497.
strands were annealed in buffer (10 mM Tris, 1 mM EDTA [pH 8.0]) Fantl, V., Stamp, G., Andrews, A., Rosewell, I., and Dickson, C.
and end-labeled using [g-32P]ATP (Amersham) and T4 polynucleo- (1995). Mice lacking cyclin D1 are small and show defects in eye
tide kinase (Boehringer Mannheim).U2-0S cell were transfectedwith and mammary gland development. Genes Dev. 9, 2364–2372.
ER in combination with cyclin D1 (2.5 mg each) in 10 cm tissue
Graham, F.L., and van der Eb, A.J. (1973). A new technique for
culture dishes. For the preparation of cell extract, cells were washed
the assay of infectivity of human adenovirus 5 DNA. Virology 52,
with cold PBS, collected, and resuspended in 100 ml ice cold extrac-
456–467.
tion buffer (0.4 M KCl, 10 mM Tris [pH 7.4], 1 mM EDTA, 2 mM DTT,
Hinds, P.W., Mittnacht, S., Dulic, V., Arnold, A., Reed, S.I., and Wein-and 10% glycerol [v/v]). The cells were kept on ice for 20 min and
berg, R.A. (1992). Regulation of retinoblastoma protein functions byspun for 10 min at 14,000 rpm and 48C. The amount of cell extract
ectopic expression of human cyclins. Cell 70, 993–1006.used for gel shift assays was adjusted for protein content and trans-
Hinds, P.W., Dowdy, S.F., Eaton, E.N., Arnold, A., and Weinberg,fection efficiency. Ten micrograms of cell extract was added to
R.A. (1994). Function of a human cyclin gene as an oncogene. Proc.incubation buffer (10 mM Tris [pH 7.5], 50 mM NaCl, 0.5 mM EDTA,
Natl. Acad. Sci. USA 91, 709–713.0.5 mM DTT, 1 mM MgCl2, 4% glycerol [v/v], 1 mg poly [dI.dC], and
1 mg ssDNA) and placed on ice. After 15 min, 0.5 ng 32P-labeled Ignar-Trowbridge, D.M., Teng, C.T., Ross, K.A., Parker, M.G., Kor-
ERE oligonucleotide was added, and the reaction was incubated ach, K.S., and McLachlan, J.A. (1993). Peptide growth factors elicit
for 20 min at room temperature. Where indicated, 2 ml antibody estrogen receptor-dependent transcriptional activation of an estro-
directed against human ER (SRA-1010, Stress Gen) was added to gen-responsive element. Mol. Endocrinol. 7, 992–998.
the reaction mixture for an additional 10 min. The protein-ERE com- Inaba, T., Matsushime, H., Valentine, M., Roussel, M.F., Sherr, C.J.,
plexes were separated on a 5% polyacrylamide gel in 0.5X TBE at and Look, A.T. (1992). Genomic organization, chromosomal localiza-
200 V for 3 hr, vacuum dried, and subjected to autoradiography. tion, and independent expression of human cyclin D genes. Geno-
mics 13, 565–574.
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